MergerAug 3, 2026, 08:38 AM
Supernus and Indivior Announce Proposed Merger of Equals
AI Summary
Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. announced a proposed merger of equals to create a diversified CNS biopharmaceutical leader. The transaction is structured as a 100% tax-free stock-for-stock merger, with Supernus shareholders receiving 1.5401 Indivior shares per Supernus share. Indivior will also declare a $1 billion dividend to its pre-closing stockholders. The combined entity, named Supernus, Inc., anticipates annual cost synergies of at least $125 million and targets closing in Q4 2026.
Key Highlights
- Proposed merger of equals between Supernus Pharmaceuticals and Indivior Pharmaceuticals.
- Supernus shareholders to receive 1.5401 Indivior shares for each Supernus share.
- Indivior to declare a $1 billion dividend to pre-closing stockholders.
- Combined company named Supernus, Inc., headquartered in Rockville, Maryland.
- Targeted closing in Q4 2026, subject to shareholder and regulatory approvals.
- Pro-forma combined net revenue of $2.162 billion (LTM as of 6/30/26).
- Expected annual cost synergies of at least $125 million.
- Post-close ownership: 56.5% Indivior shareholders, 43.5% Supernus shareholders.
Price Impact
More from SUPN